Evidence map›Paper›PMID 34448539›Full record

ArticleJournal of cachexia, sarcopenia and muscle2021

Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis.

Lisa Martin, Maurizio Muscaritoli, Isabelle Bourdel-Marchasson, Catherine Kubrak, Barry Laird, Bruno Gagnon, Martin Chasen, Ioannis Gioulbasanis, Ola Wallengren, Anne C Voss and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 10 countries.

Lisa MartinDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0003-4518-7246
Maurizio MuscaritoliDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Isabelle Bourdel-MarchassonUniversity of Bordeaux, Bordeaux, France.
Catherine KubrakDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Barry LairdUniversity of Edinburgh, European Palliative Care Research Center, Edinburgh, UK.
Bruno GagnonDepartment of Family Medicine and Emergency Medicine, Université Laval, Laval, Quebec, Canada.
Martin ChasenDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
Ioannis GioulbasanisDepartment of Medical Oncology, Αnimus-Κyanous Stavros General Clinic - Larissa, Thessaly, Greece.
Ola WallengrenClinical Nutrition Unit, Sahlgrenska University Hospital, Gothenburg, Sweden.
Anne C VossGlobal Research and Development (retired), Abbott Nutrition, Columbus, Ohio, USA.
Francois GoldwasserMedical Oncology, Cochin Hospital, APHP 5, University of Paris, Paris, France.
R Thomas JagoeMcGill Cancer Nutrition Rehabilitation Clinic, Jewish General Hospital, Montreal, Quebec, Canada.
Chris DeansClinical and Surgical Sciences, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh, UK.
Federico BozzettiFaculty of Medicine, University of Milan, Milan, Italy.
Florian StrasserOncological Palliative Medicine, Division of Oncology, Department of Internal Medicine and Palliative Care Center, Cantonal Hospital, St. Gallen, Switzerland.
Lene ThoresenOncology Clinic, St. Olavs University Hospital, Trondheim, Norway.
Sean KazemiDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Vickie BaracosDepartment of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Pierre SenesseClinical Nutrition and Gastroenterology Unit, Institut de recherche en Cancérologie de Montpellier (IRCM) Inserm U1194, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.
University of Alberta · CAAbbott (United States) · USEdinburgh Royal Infirmary · GBEuropean Association for Palliative Care · BEInserm · FRJewish General Hospital · CAKyanous Stavros Hospital · GRSahlgrenska University Hospital · SESapienza University of Rome · ITSt Olav's University Hospital · NOUniversité de Bordeaux · FRUniversité Laval · CAUniversité Paris Cité · FRUniversity of Milan · ITUniversity of St.Gallen · CHUniversity of Toronto · CA

Funding

CIHR
6 · The paper itself

Abstract

backgroundCancer-associated weight loss (WL) associates with increased mortality. International consensus suggests that WL is driven by a variable combination of reduced food intake and/or altered metabolism, the latter often represented by the inflammatory biomarker C-reactive protein (CRP). We aggregated data from Canadian and European research studies to evaluate the associations of reduced food intake and CRP with cancer-associated WL (primary endpoint) and overall survival (OS, secondary endpoint).

methodsThe data set included a total of 12,253 patients at risk for cancer-associated WL. Patient-reported WL history (% in 6 months) and food intake (normal, moderately, or severely reduced) were measured in all patients; CRP (mg/L) and OS were measured in N = 4960 and N = 9952 patients, respectively. All measures were from a baseline assessment. Clinical variables potentially associated with WL and overall survival (OS) including age, sex, cancer diagnosis, disease stage, and performance status were evaluated using multinomial logistic regression MLR and Cox proportional hazards models, respectively.

resultsPatients had a mean weight change of -7.3% (±7.1), which was categorized as: ±2.4% (stable weight; 30.4%), 2.5-5.9% (19.7%), 6.0-10.0% (23.2%), 11.0-14.9% (12.0%), ≥15.0% (14.6%). Normal food intake, moderately, and severely reduced food intake occurred in 37.9%, 42.8%, and 19.4%, respectively. In MLR, severe WL (≥15%) (vs. stable weight) was more likely (P < 0.0001) if food intake was moderately [OR 6.28, 95% confidence interval (CI 5.28-7.47)] or severely reduced [OR 18.98 (95% CI 15.30-23.56)]. In subset analysis, adjusted for food intake, CRP was independently associated (P < 0.0001) with ≥15% WL [CRP 10-100 mg/L: OR 2.00, (95% CI 1.58-2.53)] and [CRP > 100 mg/L: OR 2.30 (95% CI 1.62-3.26)]. Diagnosis, stage, and performance status, but not age or sex, were significantly associated with WL. Median OS was 9.9 months (95% CI 9.5-10.3), with median follow-up of 39.7 months (95% CI 38.8-40.6). Moderately and severely reduced food intake and CRP independently predicted OS (P < 0.0001).

conclusionsModelling WL as the dependent variable is an approach that can help to identify clinical features and biomarkers associated with WL. Here, we identify criterion values for food intake impairment and CRP that may improve the diagnosis and classification of cancer-associated cachexia.

Indexed as

CachexiaNeoplasmsCanadaCohort StudiesEatingHumansInflammationWeight LossCachexiaCancerInflammationMalnutritionReduced food intakeWeight loss

Identifiers

PMID34448539
PMCPMC8517347
OpenAlexW3194929515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.